Reported 4 days ago
Eli Lilly and Company (LLY) ranks among the top high growth dividend stocks, having consistently increased its dividends for 11 years and maintaining a strong 15.08% revenue growth over the past five years. As it prepares for pivotal phase 3 trial results for its weight management drug orforglipron, analysts project significant potential in the GLP-1 agonist market, which could exceed $150 billion by 2030. The company's reliability in dividend payments over its 139-year history makes it an attractive investment amid ongoing market fluctuations.
Source: YAHOO